Exbio — Research products — Antibodies — CD and related antigens — Anti-DLL4 Purified

Anti-DLL4 Purified

Regulatory status

RUO

Antigen

DLL4

Clone

MHD4-46

Format

Purified

Reactivity

Human

Application

FC (QC tested)

Variant

0.1 mg

11-717-C100

In stock

154.00 USD

0.025 mg

11-717-C025

Delivery 1 week

77.00 USD

Variant

0.1 mg

11-717-C100

In stock

154.00 USD

0.025 mg

11-717-C025

Delivery 1 week

77.00 USD

Contact distributor

Product details

Description

Images

References

SDS download

Isotype

Mouse IgG1 kappa

Specificity

The mouse monoclonal antibody MHD4-46 recognizes the extracellular domain of DLL4 (Delta-like ligand 4), a type I transmembrane protein which plays an important role in vascular development.

Application

FC (QC tested)

Application details

Flow cytometry: Recommended dilution: 1-4 µg/ml

Reactivity

Human

Immunogen

recombinant soluble human DLL4

Concentration

1 mg/ml

Preparation

Purified by protein-A affinity chromatography.

Formulation

Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Storage and handling

Store at 2-8°C. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Other names

DL4, AOS6

Antigen description

DLL4 (Delta-like 4) is one of five ligands of Notch receptors. It interacts with Notch1 and Notch4. DLL4 is up-regulated at sites of physiologic and pathologic angiogenesis, whereas its expression is low in most adult normal tissues. It is also highly expressed in human clear-cell renal carcinomas, bladder cancers, and breast cancers. Blocking the DLL4-Notch interaction seems to be a promissing therapeutic approach.

Entrez Gene ID 54567

UniProt ID Q9NR61

Separation of DLL4 transfected HD4 cells stained using anti-DLL4 (MHD4-46) purified antibody (concentration in sample 3 μg/ml, GAM APC, red-filled) from DLL4 transfected HD4 cells unstained by primary antibody (GAM APC, black-dashed) in flow cytometry analysis (surface staining).

Product specific references:

Yamanda S, Ebihara S, Asada M, Okazaki T, Niu K, Ebihara T, Koyanagi A, Yamaguchi N, Yagita H, Arai H: Role of ephrinB2 in nonproductive angiogenesis induced by Delta-like 4 blockade. Blood. 2009 Apr 9;113(15):3631-9
PubMed

Oishi H, Sunamura M, Egawa S, Motoi F, Unno M, Furukawa T, Habib NA, Yagita H: Blockade of delta-like ligand 4 signaling inhibits both growth and angiogenesis of pancreatic cancer. Pancreas. 2010 Aug;39(6):897-903
PubMed

Sekine C, Koyanagi A, Koyama N, Hozumi K, Chiba S, Yagita H: Differential regulation of osteoclastogenesis by Notch2/Delta-like 1 and Notch1/Jagged1 axes. Arthritis Res Ther. 2012 Mar 5;14(2):R45.
PubMed